Oculis Holding AG
OCS19.239USD
-0.241-1.24%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.07BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Oculis Holding AG Unternehmen
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Oculis Holding AG Informationen
BörsenkürzelOCS
Name des UnternehmensOculis Holding AG
IPO-datumMar 03, 2023
CEODr. Riad Sherif, M.D.
Anzahl der mitarbeiter49
WertpapierartOrdinary Share
GeschäftsjahresendeMar 03
AddresseBahnhofstrasse 20
StadtZUG
BörseNASDAQ Global Market Consolidated
LandSwitzerland
Postleitzahl6300
Telefon41417113960
Websitehttps://oculis.com/
BörsenkürzelOCS
IPO-datumMar 03, 2023
CEODr. Riad Sherif, M.D.
Führungskräfte von Oculis Holding AG
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Martijn Kleijwegt
Mr. Martijn Kleijwegt
Independent Director
Independent Director
470.97K
--
Mr. Pall Ragnar Johannesson
Mr. Pall Ragnar Johannesson
Chief Business Officer
Chief Business Officer
268.83K
+7.87%
Ms. Sylvia Cheung, CPA
Ms. Sylvia Cheung, CPA
Chief Financial Officer
Chief Financial Officer
72.06K
+7.86%
Ms. Geraldine O'Keeffe
Ms. Geraldine O'Keeffe
Independent Director
Independent Director
20.59K
--
Mr. Robert K. Warner
Mr. Robert K. Warner
Independent Director
Independent Director
--
--
Mr. Arshad M. Khanani, M.D.
Mr. Arshad M. Khanani, M.D.
Independent Director
Independent Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Riad Sherif, M.D.
Dr. Riad Sherif, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Christina M. Ackermann
Ms. Christina M. Ackermann
Independent Director
Independent Director
--
-100.00%
Mr. Lionel Carnot
Mr. Lionel Carnot
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Martijn Kleijwegt
Mr. Martijn Kleijwegt
Independent Director
Independent Director
470.97K
--
Mr. Pall Ragnar Johannesson
Mr. Pall Ragnar Johannesson
Chief Business Officer
Chief Business Officer
268.83K
+7.87%
Ms. Sylvia Cheung, CPA
Ms. Sylvia Cheung, CPA
Chief Financial Officer
Chief Financial Officer
72.06K
+7.86%
Ms. Geraldine O'Keeffe
Ms. Geraldine O'Keeffe
Independent Director
Independent Director
20.59K
--
Mr. Robert K. Warner
Mr. Robert K. Warner
Independent Director
Independent Director
--
--
Mr. Arshad M. Khanani, M.D.
Mr. Arshad M. Khanani, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Oct 25
Aktualisiert: Sat, Oct 25
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
EQT Life Sciences
9.95%
Earlybird Venture Capital
4.40%
Pivotal Bioventure Partners Investment Advisor LLC
3.98%
BVCF Management, Ltd.
3.79%
Novartis AG
2.96%
Andere
74.91%
Aktionäre
Aktionäre
Anteil
EQT Life Sciences
9.95%
Earlybird Venture Capital
4.40%
Pivotal Bioventure Partners Investment Advisor LLC
3.98%
BVCF Management, Ltd.
3.79%
Novartis AG
2.96%
Andere
74.91%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
26.04%
Corporation
3.27%
Individual Investor
3.04%
Investment Advisor/Hedge Fund
2.64%
Investment Advisor
1.99%
Hedge Fund
0.55%
Research Firm
0.09%
Bank and Trust
0.04%
Pension Fund
0.04%
Andere
62.30%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
49
16.43M
31.39%
+807.94K
2025Q2
51
19.48M
37.42%
+1.76M
2025Q1
51
19.44M
37.35%
+1.93M
2024Q4
86
15.00M
31.97%
-10.87M
2024Q3
87
16.29M
41.43%
-9.17M
2024Q2
88
16.63M
42.28%
-9.14M
2024Q1
91
16.14M
42.22%
-11.25M
2023Q4
93
17.20M
46.87%
-6.97M
2023Q3
92
16.51M
48.34%
-4.37M
2023Q2
91
16.72M
48.91%
-4.14M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
EQT Life Sciences
5.75M
10.99%
+425.53K
+7.99%
Dec 31, 2024
Earlybird Venture Capital
2.54M
4.86%
+2.54M
--
Dec 31, 2024
Pivotal Bioventure Partners Investment Advisor LLC
2.30M
4.4%
--
--
Jun 30, 2025
BVCF Management, Ltd.
2.19M
4.19%
+121.79K
+5.88%
Nov 27, 2024
Novartis AG
1.71M
3.27%
-464.38K
-21.32%
Feb 13, 2024
abrdn Inc.
1.25M
2.39%
--
--
Jun 30, 2025
Sherif (Riad M.D.)
644.75K
1.23%
-233.73K
-26.61%
Dec 31, 2024
Stefnir hf.
540.50K
1.03%
--
--
Aug 31, 2025
Nan Fung Life Sciences
514.70K
0.98%
--
--
Jun 30, 2025
Kleijwegt (Martijn)
470.97K
0.9%
+470.97K
--
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Name
Anteil
SPDR SSGA US Small Cap Low Volatility Index ETF
0.11%
Even Herd Long Short ETF
0%
SPDR SSGA US Small Cap Low Volatility Index ETF
Anteil0.11%
Even Herd Long Short ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
